I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. 

This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings.

For our Council discussion, I would like to get an understanding as to: 

• whether a Board liaison is already expected (and so we should remind the Board of this)
• if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and
• to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective.